Citius Oncology Statistics

Total Valuation

Citius Oncology has a market cap or net worth of $76.53 million. The enterprise value is $73.61 million.

Market Cap	76.53M
Enterprise Value	73.61M

Important Dates

The next estimated earnings date is Wednesday, May 13, 2026, after market close.

Earnings Date	May 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Citius Oncology has 88.28 million shares outstanding. The number of shares has increased by 11.84% in one year.

Current Share Class	88.28M
Shares Outstanding	88.28M
Shares Change (YoY)	+11.84%
Shares Change (QoQ)	+11.54%
Owned by Insiders (%)	0.02%
Owned by Institutions (%)	1.54%
Float	14.13M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	19.55
Forward PS	1.26
PB Ratio	1.27
P/TBV Ratio	1.32
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	18.66
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.83, with a Debt / Equity ratio of 0.07.

Current Ratio	0.83
Quick Ratio	0.25
Debt / Equity	0.07
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-84.81

Financial Efficiency

Return on equity (ROE) is -47.41% and return on invested capital (ROIC) is -26.07%.

Return on Equity (ROE)	-47.41%
Return on Assets (ROA)	-13.96%
Return on Invested Capital (ROIC)	-26.07%
Return on Capital Employed (ROCE)	-34.29%
Weighted Average Cost of Capital (WACC)	22.31%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.04
Inventory Turnover	0.04

Taxes

In the past 12 months, Citius Oncology has paid $1.06 million in taxes.

Income Tax	1.06M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +18.90% in the last 52 weeks. The beta is 3.44, so Citius Oncology's price volatility has been higher than the market average.

Beta (5Y)	3.44
52-Week Price Change	+18.90%
50-Day Moving Average	0.86
200-Day Moving Average	1.36
Relative Strength Index (RSI)	54.93
Average Volume (20 Days)	158,164

Short Selling Information

The latest short interest is 934,868, so 1.06% of the outstanding shares have been sold short.

Short Interest	934,868
Short Previous Month	1.06M
Short % of Shares Out	1.06%
Short % of Float	6.62%
Short Ratio (days to cover)	4.76

Income Statement

In the last 12 months, Citius Oncology had revenue of $3.94 million and -$23.64 million in losses. Loss per share was -$0.31.

Revenue	3.94M
Gross Profit	3.15M
Operating Income	-22.38M
Pretax Income	-22.58M
Net Income	-23.64M
EBITDA	n/a
EBIT	-22.38M
Loss Per Share	-$0.31

Full Income Statement

Balance Sheet

The company has $7.30 million in cash and $3.80 million in debt, giving a net cash position of $3.50 million or $0.04 per share.

Cash & Cash Equivalents	7.30M
Total Debt	3.80M
Net Cash	3.50M
Net Cash Per Share	$0.04
Equity (Book Value)	58.41M
Book Value Per Share	0.69
Working Capital	-7.56M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-12.85M
Capital Expenditures	n/a
Depreciation & Amortization	n/a
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	79.99%
Operating Margin	-567.43%
Pretax Margin	-572.48%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Citius Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.84%
Shareholder Yield	-11.84%
Earnings Yield	-30.65%
FCF Yield	n/a

Analyst Forecast

The average price target for Citius Oncology is $6.00, which is 592.12% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$6.00
Price Target Difference	592.12%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Citius Oncology has an Altman Z-Score of -0.29 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.29
Piotroski F-Score	2